Shared on 11 Sep 25
Fair value Increased 21%Despite a decline in net profit margin, Coherus Oncology's significantly higher future P/E ratio reflects increased investor optimism, resulting in a raised consensus price target from $4.70 to $5.67. What's in the News Coherus Oncology received a deficiency notice from Nasdaq after its common stock closed below $1.00 per share for 30 consecutive business days, putting it at risk of delisting.
Shared on 17 Apr 25
Fair value Increased 4.84%AnalystConsensusTarget has decreased profit margin from 19.3% to 17.3%.